Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopat.
References:
[1]. Lorenzo RD, et, al. Begelomab for severe refractory dermatomyositis: A case report. Medicine (Baltimore). 2021 Mar 5;100(9):e24372.
[2]. Ojha R, et, al. Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. Hum Immunol. 2022 Apr;83(4):346-355.